1 to 10 of 16 literature results

• A conditional mouse model for malignant mesothelioma.

  Malignant mesothelioma is a devastating disease that has been associated with loss of Neurofibromatosis type 2 (NF2) and genetic lesions affecting RB …

  Authors: Johan Jongsma, Erwin van Montfort, Marc Vooijs, John Zevenhoven, Paul Krimpenfort, Martin van der Valk, Marc van de Vijver, Anton Berns

  Source: Cancer cell. 2008 Mar

  View Full Text

• Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

  ER, PR and HER2 status in breast cancer are important markers for the selection of drug therapy. By immunohistochemistry (IHC), three major breast can…

  Authors: Jorma J de Ronde, Juliane Hannemann, Hans Halfwerk, Lennart Mulder, Marieke E Straver, Marie-Jeanne T F D Vrancken Peeters, Jelle Wesseling, Marc van de Vijver, Lodewyk F A Wessels, Sjoerd Rodenhuis

  Source: Breast cancer research and treatment. 2010 Jan

  View Full Text

• Emerging technologies for assessing HER2 amplification.

  Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of…

  Authors: Frédérique Penault-Llorca, Michael Bilous, Mitch Dowsett, Wedad Hanna, Robert Yoshiyuki Osamura, Josef Rüschoff, Marc van de Vijver

  Source: American journal of clinical pathology. 2009 Oct

  View Full Text

• A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.

  Breast cancer comprises a group of distinct subtypes that despite having similar histologic appearances, have very different metastatic potentials. Be…

  Authors: Hongyue Dai, Laura van't Veer, John Lamb, Yudong D He, Mao Mao, Bernard M Fine, Rene Bernards, Marc van de Vijver, Paul Deutsch, Alan Sachs,…

  Source: Cancer research. 2005 May 15

  View Full Text

• Improving patient care through molecular diagnostics.

  Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assess…

  Authors: Edith A Perez, Lajos Pusztai, Marc Van de Vijver

  Source: Seminars in oncology. 2004 Oct

  View Full Text

• Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.

  INTRODUCTION: The Preoperative Chemotherapy in Primary Operable Breast Cancer (POCOB) study was designed to compare preoperative with postoperative ch…

  Authors: Johanna G H van Nes, Hein Putter, Jean-Pierre Julien, Michelle Tubiana-Hulin, Marc van de Vijver, Jan Bogaerts, Monika de Vos, Cornelis J H van de Velde, Cooperating Investigators of the EORTC

  Source: Breast cancer research and treatment. 2009 May

  View Full Text

• HER-2 amplification is highly homogenous in gastric cancer.

  Authors: Michael Bilous, Robert Y Osamura, J Rüschoff, Marc van de Vijver, Wedad Hanna, Frederique Penault-Llorca, Patrick Roche

  Source: Human pathology. 2010 Feb

  View Full Text

• Emerging technologies for HER2 testing.

  HER2-positive status is the sole criterion for identifying patients with breast cancer for Herceptin therapy, which has known efficacy in women with m…

  Authors: Marc van de Vijver

  Source: Oncology. 2002

  View Full Text

• Gene-expression profiling and the future of adjuvant therapy.

  Gene-expression profiling can help distinguish between patients at high risk and those at low risk for developing distant metastases, and so identify …

  Authors: Marc van de Vijver

  Source: The oncologist. 2005 Oct

  View Full Text

• Radiation-associated breast tumors display a distinct gene expression profile.

  PURPOSE: Women who received irradiation for Hodgkin's lymphoma have a strong increased risk for developing breast cancer. Approximately 90% of the bre…

  Authors: Annegien Broeks, Linde M Braaf, Lodewyk F A Wessels, Marc van de Vijver, Marie L De Bruin, Marilyn Stovall, Nicola S Russell, Flora E van Leeuwen, Laura J Van 't Veer

  Source: International journal of radiation oncology, biology, physics. 2010 Feb 1

  View Full Text